Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | CA12 | O43570 | 10/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 9/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 8/20 | 0.42 |
| ▸ | CA2 | P00918 | 7/20 | 0.42 |
| ▸ | CA7 | P43166 | 7/20 | 0.42 |
| ▸ | CA1 | P00915 | 6/20 | 0.42 |
| ▸ | CA3 | P07451 | 5/20 | 0.42 |
| ▸ | CA4 | P22748 | 5/20 | 0.42 |
| ▸ | CA6 | P23280 | 5/20 | 0.42 |
| ▸ | CA5A | P35218 | 5/20 | 0.42 |
| ▸ | CA13 | Q8N1Q1 | 5/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23650051 | 0.94 | TSHR (0.56) | TSHRCA12CA14LMNAALDH1A1 | |
| SCHEMBL26611327 | 0.92 | TSHR (0.54) | TSHRCA12CA14LMNAALDH1A1 | |
| SCHEMBL26611365 | 0.92 | TSHR (0.54) | TSHRCA12CA14LMNAALDH1A1 | |
| SCHEMBL26611174 | 0.92 | TSHR (0.54) | TSHRCA12CA14LMNAALDH1A1 | |
| SCHEMBL23650054 | 0.92 | TSHR (0.54) | TSHRCA12CA14LMNAALDH1A1 | |
| SCHEMBL23650053 | 0.92 | TSHR (0.54) | TSHRCA12CA14LMNAALDH1A1 | |
| SCHEMBL26611184 | 0.92 | TSHR (0.54) | TSHRCA12CA14LMNAALDH1A1 | |
| SCHEMBL1621069 | 0.86 | TSHR (0.55) | TSHRCA12CA14LMNAALDH1A1 | |
| SCHEMBL17188350 | 0.80 | TSHR (0.61) | TSHRCA12CA14LMNAALDH1A1 | |
| SCHEMBL4968131 | 0.80 | TSHR (0.61) | TSHRCA12CA14LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106518850-B | A kind of chemical synthesis process of pimobendan | 青岛农业大学 | 2019-04-09 | — | — | CN | claimed |
| US-12168653-B2 | Sulfonamide derivates as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-12-17 | — | — | US | disclosed |
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-07-09 | — | — | US | disclosed |
| EP-3880666-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-06-28 | — | — | EP | disclosed |
| US-20230024859-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| US-20230024859-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| WO-2020102100-A9 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-01-06 | — | — | WO | disclosed |
| EP-3880666-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| CN-113166081-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-11040048-B2 | Medicament for treating influenza characterized by combining a Cap-dependent endonuclease inhibitor and an anti-influenza drug | SHIONOGI & CO., LTD. (JP) | 2021-06-22 | — | — | US | disclosed |
| EP-1667724-A2 | ALBUMIN-BINDING DERIVATIVES OF THERAPEUTIC PEPTIDES | NOVO NORDISK A/S (DK) | 2006-06-14 | — | — | EP | disclosed |
| CN-1784423-A | Peptides for use in treating obesity | NOVO NORDISK AS (DK) | 2006-06-07 | — | — | CN | disclosed |
| WO-2006048452-A2 | PEPTIDES FOR USE IN TREATING OF OBESITY | NOVO NORDISK A/S (DK) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006048451-A1 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006048449-A2 | MC4R SELECTIVE PEPTIDES AND THEIR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006048450-A2 | PEPTIDES FOR USE IN THE TREATING OBESITY | NOVO NORDISK A/S (DK) | 2006-05-11 | — | — | WO | disclosed |
| EP-1625158-A2 | PEPTIDES FOR USE IN TREATING OBESITY | NOVO NORDISK A/S (DK) | 2006-02-15 | — | — | EP | disclosed |
| WO-2006005667-A2 | POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY | NOVO NORDISK A/S (DK) | 2006-01-19 | — | — | WO | disclosed |
| WO-2005028516-A2 | ALBUMIN-BINDING DERIVATIVES OF THERAPEUTIC PEPTIDES | NOVO NORDISK A/S (DK) | 2005-03-31 | — | — | WO | disclosed |
| WO-2004099246-A2 | PEPTIDES FOR USE IN TREATING OBESITY | NOVO NORDISK A/S (DK) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | TSHR 2925/4885CA12 3218/4885CA14 3723/4885 |
| US-20230024859-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | TSHR 4300/4885CA12 2983/4885CA14 3599/4885 |
| US-12168653-B2 | Sulfonamide derivates as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | TSHR 2712/4885CA12 3606/4885CA14 3937/4885 |
| US-11040048-B2 | Medicament for treating influenza characterized by combining a Cap-dependent endonuclease inhibitor and an anti-influenza drug | RNASEH1, RNPEP, RNASEL | TSHR 915/4885CA12 146/4885CA14 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.